Tag Archives: TSRO

Best Warren Buffett Stocks To Buy For 2019

Apple, which already held the crown as the nation’s most-valuable company, made Wall Street history Thursday when it became the first publicly traded U.S. corporation to reach a market value of $1 trillion.

Apple, whose stock is owned by investors ranging from billionaire Warren Buffett to mutual fund giant Vanguard to millions of working Americans through funds owned in their 401(k)s, passed the milestone days after reporting another stellar quarter, highlighted by a jump in revenue to $53.3 billion and the sale of 41.3 million iPhones.

The iPhone maker broke the $1 trillion barrier when its stock briefly hit the magic share price of $207.05, according to Nanex, which supplies market data to the financial industry. Online brokerage TD Ameritrade said the history-making trade occurred at 11:48 a.m. ET.

Best Warren Buffett Stocks To Buy For 2019: First Horizon National Corporation(FHN)

Advisors’ Opinion:

  • [By Logan Wallace]

    First Horizon National (NYSE:FHN) will be posting its quarterly earnings results before the market opens on Thursday, July 12th.

    First Horizon National (NYSE:FHN) last posted its earnings results on Friday, April 13th. The financial services provider reported $0.34 EPS for the quarter, topping the Zacks’ consensus estimate of $0.30 by $0.04. First Horizon National had a return on equity of 9.37% and a net margin of 12.30%. The business had revenue of $437.20 million for the quarter, compared to analysts’ expectations of $438.60 million. During the same quarter in the previous year, the firm earned $0.23 earnings per share. The business’s revenue was up 42.6% compared to the same quarter last year. On average, analysts expect First Horizon National to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

  • [By Joseph Griffin]

    Cadence Capital Management LLC boosted its holdings in First Horizon National Corp (NYSE:FHN) by 173.5% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 30,515 shares of the financial services provider’s stock after buying an additional 19,357 shares during the quarter. Cadence Capital Management LLC’s holdings in First Horizon National were worth $544,000 at the end of the most recent reporting period.

  • [By Logan Wallace]

    Brown Advisory Inc. grew its holdings in First Horizon National Corp (NYSE:FHN) by 117.2% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 65,240 shares of the financial services provider’s stock after acquiring an additional 35,197 shares during the quarter. Brown Advisory Inc.’s holdings in First Horizon National were worth $1,164,000 as of its most recent filing with the Securities and Exchange Commission.

  • [By ]

    In an “Executive Decision” segment, Cramer sat down with Bryan Jordan, chairman, president and CEO of First Horizon National (FHN) , the Tennessee-based regional bank that just posted a three-cents-a-share earnings beat with net interest margins up 52 basis points.

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on First Horizon National (FHN)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Best Warren Buffett Stocks To Buy For 2019: GlaxoSmithKline PLC(GSK)

Advisors’ Opinion:

  • [By Keith Speights]

    It’s been a very different year so far for two big pharma stocks: One’s hot and one’s not. Things are going great for GlaxoSmithKline plc (NYSE:GSK) as its share price is up around 15% year to date. But for Johnson & Johnson (NYSE:JNJ), it’s a different story. J&J stock is down more than 10% in 2018.

  • [By George Budwell]

    After a prolonged downturn, British pharma goliath GlaxoSmithKline (NYSE:GSK) has finally started to recapture the imagination of Wall Street. The overwhelming majority of analysts covering the stock, for instance, have a favorable rating on Glaxo’s shares right now, and large institutional investors have been slowly upping their positions in this downtrodden big pharma equity in recent quarters.    

  • [By Chris Lange]

    GlaxoSmithKline PLC (NYSE: GSK) has a meeting with the FDA’s Pulmonary-Allergy Drugs Advisory Committee scheduled for July 25. The meeting is in regards to the firm’s supplementary Biologics License Agreement (sBLA) for its chronic obstructive pulmonary disease (COPD) treatment, mepolizumab.

  • [By ]

    HSBC’s top stocks list is mostly dominated by large-cap plays that happen to pay attractive dividend yields. More importantly, the stocks already have a decent amount of momentum behind them: the average one-month performance is +5.5%. 

    Baker Hughes (BHGE) Tiffany & Co. (TIF) The Mosaic Company (MOS) Deutsche Telekom Schneider Electric Adidas (ADDYY) Unicredit  CRH (CRH) Luftansa  GlaxosmithKline (GSK) Associated British Foods   Fresnillo China Construction Bank China Overseas Land & Inv. Geely Automobile Holdings CRCC China Resources Beer Samsung Electronic Sasol Adani Ports and SEZ

  • [By Keith Speights]

    GlaxoSmithKline (GSK), like Teva, lost ground last year, with its stock declining by nearly 8%. So far in 2018, though, GSK’s share price is up more than 12% — trouncing the major indexes.

Best Warren Buffett Stocks To Buy For 2019: TransAct Technologies Incorporated(TACT)

Advisors’ Opinion:

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on TransAct Technologies (TACT)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Ethan Ryder]

    Logitech (NASDAQ: LOGI) and TransAct Technologies (NASDAQ:TACT) are both computer and technology companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability.

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on TransAct Technologies (TACT)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Ethan Ryder]

    TransAct Technologies Incorporated (NASDAQ:TACT) Chairman Bart C. Shuldman sold 1,272 shares of TransAct Technologies stock in a transaction dated Tuesday, September 4th. The stock was sold at an average price of $14.35, for a total value of $18,253.20. Following the completion of the transaction, the chairman now directly owns 18,205 shares in the company, valued at approximately $261,241.75. The sale was disclosed in a document filed with the SEC, which is available at this link.

Best Warren Buffett Stocks To Buy For 2019: TESARO, Inc.(TSRO)

Advisors’ Opinion:

  • [By Chris Lange]

    Buy-dip on several “Potential Blockbusters” Aimmune Therapeutics, Inc. (NASDAQ: AIMT), Audentes Therapeutics, Inc. (NASDAQ: BOLD), AveXis, Inc. (NASDAQ: AVXS), Bluebird Bio, Inc. (NASDAQ: BLUE), Esperion Therapeutics, Inc. (NASDAQ: ESPR), and Sage Therapeutics, Inc. (NASDAQ: SAGE) are buy-dip candidates given their bullish trends and favorable technical patterns. Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), Prothena Corp. PLC (NASDAQ: PRTA), Tesaro, Inc. (NASDAQ: TSRO) and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) have bearish set-ups. Heron Therapeutics, Inc. (NASDAQ: HRTX) is bigger picture bullish, but may correct further on a move below $19.55. Clovis Oncology, Inc. (NASDAQ: CLVS) has bearish set-up and bulls need to push above $69 to invalidate.

  • [By Brian Orelli]

    The phase 2 TOPACIO/Keynote-162 trial tests Tesaro’s (NASDAQ:TSRO) poly (ADP-ribose) polymerase (PARP) inhibitor, Zejula, with Keytruda. On Sunday, outcomes for patients with recurrent ovarian cancer will be presented, as Tesaro and Merck look to build on earlier promising results. Then on Monday, the duo will present data testing the combination in patients with metastatic triple-negative breast cancer as Tesaro looks to expand the market for Zejula.

  • [By Cory Renauer]

    All of these biotech stocks have been battered for different reasons, and bouncing back will be a lot easier for some than for others. 

    Company (Symbol) One-Month Loss  Market Capitalization
    Idera Pharmaceuticals (NASDAQ:IDRA) (35%) $199.7 million
    Spark Therapeutics (NASDAQ:ONCE) (38%) $2.16 billion
    Tesaro (NASDAQ:TSRO) (40%) $1.49 billion

    Here’s what needs to happen if these stocks are going to mount a comeback.

  • [By Todd Campbell]

    Tesaro, Inc. (NASDAQ:TSRO) shares are rallying this week on rumors it’s an acquisition target. The company, which markets two cancer drugs, recently increased its sales guidance because of growing demand. Given that shares are trading at a steep discount to where they were last year, it could be the perfect time for a suitor to come knocking. Here’s what investors should know about this company and why it could be attractive to a buyer.

  • [By Paul Ausick]

    Tesaro Inc. (NASDAQ: TSRO) traded down about 10% Tuesday and posted a new 52-week low of $74.57 after Friday at $82.87. The 52-week high is $192.94. Volume was about 2 million, more than double the daily average of around 870,000 million shares. The maker of cancer therapeutics had no specific news.

Hot Clean Energy Stocks To Invest In Right Now

What happened 

Shares of natural gas fuel supplier Clean Energy Fuels Corp (NASDAQ:CLNE) jumped as much as 12% in trading Tuesday as oil prices continued to help push the stock higher. At 3:30 p.m. EDT shares were near their high for the day, trading 11.6% higher. 

So what

The ups and downs of crude oil trading can often drive Clean Energy Fuels’ stock and that appears to be what’s happening today. Midday, oil prices spiked on news that the Trump Administration would ban all oil imports from Iran by Nov. 4, 2018. WTI Crude Oil is trading 3.5% higher at $70.45 per barrel and Brent Crude is currently up 2.2% to $76.34 per barrel.

Image source: Getty Images.

Since Clean Energy Fuels’ natural gas products are a direct competitor to diesel, which comes from crude oil, when oil prices rise it makes natural gas more competitive. For today, investors are speculating that rising oil prices will eventually help the company’s financials. 

Hot Clean Energy Stocks To Invest In Right Now: Insmed, Inc.(INSM)

Advisors’ Opinion:

  • [By Chris Lange]

    Insmed Inc. (NASDAQ: INSM) previously announced that the FDA’s Antimicrobial Drugs Advisory Committee voted 12 to two in favor of the safety and effectiveness of ALIS (amikacin liposome inhalation suspension) for adults with nontuberculous mycobacterial lung disease caused by Mycobacterium avium complex who have limited or no treatment options. Expect a PDUFA date on September 28.

  • [By Max Byerly]

    TRADEMARK VIOLATION WARNING: “TIAA CREF Investment Management LLC Buys 13,438 Shares of Insmed, Inc. (INSM)” was first posted by Ticker Report and is the property of of Ticker Report. If you are viewing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this article can be accessed at www.tickerreport.com/banking-finance/3353518/tiaa-cref-investment-management-llc-buys-13438-shares-of-insmed-inc-insm.html.

  • [By Stephan Byrd]

    Insmed Incorporated (NASDAQ:INSM) has been given an average rating of “Buy” by the ten research firms that are presently covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $33.57.

Hot Clean Energy Stocks To Invest In Right Now: Renewable Energy Group, Inc.(REGI)

Advisors’ Opinion:

  • [By Max Byerly]

    Renewable Energy Group Inc (NASDAQ:REGI) was the target of some unusual options trading activity on Thursday. Stock traders acquired 728 call options on the company. This is an increase of approximately 522% compared to the average daily volume of 117 call options.

  • [By Max Byerly]

    Methanex (NASDAQ: REGI) and Renewable Energy Group (NASDAQ:REGI) are both basic materials companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation and dividends.

  • [By Maxx Chatsko]

    Three growth stocks I’d buy right now are animal health leader Zoetis (NYSE:ZTS), ready-mix concrete specialist U.S. Concrete (NASDAQ:USCR), and leading biodiesel producer Renewable Energy Group (NASDAQ:REGI). Here’s why.

Hot Clean Energy Stocks To Invest In Right Now: Eco-Stim Energy Solutions, Inc.(ESES)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on Eco-Stim Energy Solutions (ESES)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Joseph Griffin]

    Hurricane Energy (OTCMKTS: HRCXF) and Eco-Stim Energy Solutions (NASDAQ:ESES) are both small-cap oils/energy companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, institutional ownership and valuation.

  • [By Ethan Ryder]

    Press coverage about Eco-Stim Energy Solutions (NASDAQ:ESES) has trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm scores the sentiment of press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Eco-Stim Energy Solutions earned a daily sentiment score of 0.12 on Accern’s scale. Accern also assigned media coverage about the oil and gas company an impact score of 47.1001025646776 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Hot Clean Energy Stocks To Invest In Right Now: TESARO, Inc.(TSRO)

Advisors’ Opinion:

  • [By Todd Campbell]

    Rumors of a potential acquisition have been swirling for a while, yet shares in Tesaro Inc. (NASDAQ:TSRO) still soared 14.2% at 2 p.m. EDT today following reports that a bid could be near.

  • [By Max Byerly]

    TESARO Inc (NASDAQ:TSRO) – Equities researchers at Leerink Swann issued their Q3 2018 EPS estimates for TESARO in a report issued on Monday, September 24th. Leerink Swann analyst A. Berens anticipates that the biopharmaceutical company will post earnings per share of ($2.77) for the quarter. Leerink Swann has a “Outperform” rating and a $48.00 price target on the stock. Leerink Swann also issued estimates for TESARO’s Q4 2018 earnings at ($2.77) EPS, FY2018 earnings at ($11.55) EPS, FY2019 earnings at ($8.53) EPS and FY2020 earnings at ($3.58) EPS.

  • [By Dan Caplinger]

    Friday was a good day on Wall Street, especially for the large companies that make up the broadest major benchmarks. Market participants didn’t let a slightly weak July employment report rain on their parade, instead insisting that the long-term course of the U.S. economy still looks overwhelmingly positive. Nevertheless, that general sentiment wasn’t enough to prevent some stocks from posting considerable losses. Shake Shack (NYSE:SHAK), Tesaro (NASDAQ:TSRO), and Square (NYSE:SQ) were among the worst performers on the day. Here’s why they did so poorly.

  • [By Cory Renauer]

    All of these biotech stocks have been battered for different reasons, and bouncing back will be a lot easier for some than for others. 

    Company (Symbol) One-Month Loss  Market Capitalization
    Idera Pharmaceuticals (NASDAQ:IDRA) (35%) $199.7 million
    Spark Therapeutics (NASDAQ:ONCE) (38%) $2.16 billion
    Tesaro (NASDAQ:TSRO) (40%) $1.49 billion

    Here’s what needs to happen if these stocks are going to mount a comeback.

Hot Clean Energy Stocks To Invest In Right Now: SPX FLOW, Inc.(FLOW)

Advisors’ Opinion:

  • [By Max Byerly]

    Get a free copy of the Zacks research report on SPX Flow (FLOW)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Max Byerly]

    Get a free copy of the Zacks research report on SPX Flow (FLOW)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Shane Hupp]

    Shares of Flowgroup PLC (LON:FLOW) were up 5% during mid-day trading on Wednesday . The company traded as high as GBX 0.01 ($0.00) and last traded at GBX 0.01 ($0.00). Approximately 27,087,413 shares changed hands during mid-day trading, a decline of 20% from the average daily volume of 34,010,000 shares. The stock had previously closed at GBX 0.01 ($0.00).

  • [By Logan Wallace]

    Here are some of the media stories that may have effected Accern Sentiment’s rankings:

    Get SPX Flow alerts:

    Commit To Buy SPX Flow At $40, Earn 6.7% Annualized Using Options (nasdaq.com) Q3 2018 EPS Estimates for SPX Flow Inc (FLOW) Decreased by Seaport Global Securities (americanbankingnews.com) SPX FLOW, Inc. (FLOW) CEO Marc Michael on Q2 2018 Results – Earnings Call Transcript (seekingalpha.com) SPX Flow Inc (FLOW) Receives Consensus Recommendation of “Hold” from Analysts (americanbankingnews.com)

    A number of brokerages have commented on FLOW. Zacks Investment Research cut shares of SPX Flow from a “hold” rating to a “sell” rating in a research report on Saturday, July 14th. Bank of America upped their price target on shares of SPX Flow from $32.00 to $48.00 and gave the company an “underperform” rating in a research report on Thursday, August 2nd. Wolfe Research began coverage on shares of SPX Flow in a research report on Wednesday, June 27th. They set a “market perform” rating on the stock. Stifel Nicolaus upped their price target on shares of SPX Flow from $60.00 to $61.00 and gave the company a “buy” rating in a research report on Monday, April 16th. Finally, ValuEngine raised shares of SPX Flow from a “hold” rating to a “buy” rating in a research report on Wednesday, July 25th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $52.43.

Hot Clean Energy Stocks To Invest In Right Now: MEI Pharma, Inc.(MEIP)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Red Violet, Inc. (NASDAQ: RDVT) rose 75.31 percent to close at $9.94 after reporting Q1 results.
    Euro Tech Holdings Company Limited (NASDAQ: CLWT) shares jumped 40.62 percent to close at $4.50 on Tuesday after reporting 2017 year-end results.
    MEI Pharma, Inc. (NASDAQ: MEIP) gained 34.39 percent to close at $3.40.
    MEDIGUS Ltd/S ADR (NASDAQ: MDGS) gained 32.74 percent to close at $1.50 in reaction to its Monday announcement of a distribution agreement. The medical device company said it reached an agreement to distribute its minimally invasive medical devices in Turkey, Azerbaijan and Georgia.
    Pfenex Inc. (NYSE: PFNX) surged 31.15 percent to close at $8.00 after the company announced the positive top-line PF708 study results in Osteoporosis patients that showed no imbalances in severity or incidence of adverse events.
    Arcadia Biosciences, Inc. (NASDAQ: RKDA) rose 21.07 percent to close at $11.09. Arcadia Biosciences reported that Albert D. Bolles, Ph.D. has joined its board of directors.
    Genprex, Inc. (NASDAQ: GNPX) rose 20.23 percent to close at $10.58.
    Turtle Beach Corporation (NASDAQ: HEAR) shares gained 17.62 percent to close at $17.82.
    Aptevo Therapeutics Inc. (NASDAQ: APVO) rose 17.1 percent to close at $5.82.
    Phoenix New Media Limited (NYSE: FENG) shares jumped 16.23 percent to close at $4.87 following Q1 earnings.
    Stein Mart, Inc. (NASDAQ: SMRT) rose 16.04 percent to close at $3.69.
    PPDAI Group Inc. (NASDAQ: PPDF) climbed 15.99 percent to close at $7.98 following Q1 results.
    Tyme Technologies, Inc. (NASDAQ: TYME) rose 15.93 percent to close at $3.42.
    LiqTech International, Inc. (NASDAQ: LIQT) gained 15.59 percent to close at $0.5532 following Q1 results.
    Sophiris Bio, Inc. (NASDAQ: SPHS) gained 13.92 percent to close at $3.52 on Tuesday following Q1 results.
    Euroseas Ltd. (NASDAQ: ESEA) jumped 13.4 percent to close at $2.37.
    Iteris, Inc. (NASDAQ: ITI) shares surged 13.05 percent to close
  • [By Logan Wallace]

    Get a free copy of the Zacks research report on MEI Pharma (MEIP)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Ethan Ryder]

    Shares of MEI Pharma Inc (NASDAQ:MEIP) were up 13.2% during trading on Wednesday . The company traded as high as $4.30 and last traded at $4.30. Approximately 651,334 shares were traded during trading, an increase of 127% from the average daily volume of 287,125 shares. The stock had previously closed at $3.80.

Hot Performing Stocks To Own Right Now

In Johnson & Johnson news, the stock is down 1.3% over the last five trading days, and that makes this the perfect time to buy this dividend aristocrat…

The pullback was caused by two analysts downgrading Johnson & Johnson (NYSE: JNJ) on July 21, but analysts simply don’t know how to value JNJ stock.

BTIG Research downgraded JNJ from “Neutral” to “Sell” because it doesn’t think Johnson & Johnson will be able to successfully execute its medical device acquisition.

Alembic Global Advisors downgraded the company from “Neutral” to “Underperforming” but didn’t release its rationale.

Hot Performing Stocks To Own Right Now: TESARO, Inc.(TSRO)

Advisors’ Opinion:

  • [By Todd Campbell]

    The PARP battle is on. Following news that AstraZeneca’s (NYSE:AZN) PARP-inhibiting cancer drug Lynparza delivered a big win in phase 3 studies, all eyes now shift to how a potential Food and Drug Administration approval for Lynparza will reshape the commercial opportunity for competitor Tesaro Inc. (NASDAQ:TSRO).

  • [By Ben Levisohn]

    Shares of Tesaro (TSRO) are soaring today after the biotech company reported positive data for its treatment of ovarian cancer over the weekend. Credit Suisse analyst Alethia Young and team contend that “M&A remains in focus” for Tesaro following the data:

    Getty Images

    We are increasing our target price to $122 from $90 as we move to an M&A DCF valuation. We were at ESMO this weekend, and we believe the big takeaway on Tesaro data is that it works broadly in all 2L ovarian populations and safety looks solid. We also think the robustness of this data bodes well from PRIMA and QUADRA but are maintaining our POS here. We have looked at our model and also adjusted durations in first-line. We think Tesaro remains one of the most attractive and de-risked cancer assets in our landscape and the company has been cited in major press sources as a takeout target (Bloomberg, Investor Business Daily).

    We think M&A remains in focus for Tesaro. Our M&A DCF valuations range from $122 to $157 by our model. We have also built models for other cancers like NSCLC, SCLC, prostate, and others where PARP might be impactful. We assume 0% POS for now but we conservatively see at least another $1B in sales from PARP expansion. Tesaro has been cited in the press as a potential M&A target and is a company we frequently hear mentioned as a target from our conversations. We think the demand for late stage oncology assets is high, especially in the PARP space given the potential for activity across a range of tumors. For a large Pharma player who already has an oncology salesforce and large R&D infrastructure we could see SG&A synergies of 50-75% and R&D synergies of 15-30%. In our base case TSRO P&L we model a tax rate of 30% so there could be synergies here as well. Two additional key swing factors which might be included in a CVR are how much expansion from PARP in other cancers and immuno-oncology…

    Ex M&A,

  • [By Todd Campbell]

    Tesaro’s (NASDAQ:TSRO)ovarian cancer drug, niraparib, will begin competing for prescriptions earlier than expected. Niraparib, which will be sold under the brand name Zejula, notched FDA approval on Monday, more than three months ahead of its June 30 decision date. The early approval setsTesaro up for a fierce battle for market share withAstraZeneca (NYSE:AZN)and Clovis Oncology (NASDAQ:CLVS), both of which market drugs that work similarly to Zejula.

  • [By Ben Levisohn]

    Look out below! Shares of Tesaro (TSRO) have dropped more than 10% this afternoon after AstraZeneca (AZN) released stronger-than-expected Phase 3 trial data on a its ovarian cancer treatment.

    Agence France-Presse/Getty Images

    The Street’sAdam Feuerstein has the details on AstraZeneca’s strong data and its impact on Tesaro:

    AstraZeneca’s (AZN) PARP inhibitor Lynparza delayed the recurrence of ovarian cancer by more than two years compared to a placebo, according to results from a phase III study presented Tuesday.

    The strong benefit observed with Lynparza as ovarian cancer maintenance therapy exceeded investor expectations and bolsters AstraZeneca against a competing PARP inhibitor from Tesaro (TSRO).

    Feuerstein also notes that AstraZeneca’s data could be good newsClovis Oncology (CLVS), which also had a PARP inhibitor approved recently, if it means that its drug could work as well as Astra’s.

    In February, Leerink cut Tesaro, arguing that the rally in its shares due to a potential takeover had run too far. Will it still be a takeover target?

    Shares of Tesaro have dropped 14% to $148.01 at 3:28 p.m. today, while AstraZeneca has gained 1.1% to $30.41, and Clovis Oncology has jumped 9.8% to$66.55.

    UPDATE:Piper Jaffray’sSteven Breazzano andJoshua Schimmer note that the AstraZeneca data shows that PARPs are “more similar than different.” They explain:

    This afternoon AstraZeneca (covered by PJC analyst Richard Purkiss) reported the detailed results from the SOLO-2 maintenance study of Lynparza in 2L+ ovarian cancer. The detailed data highlights a PFS benefit of 14 months (investigator assessed, and primary endpoint) and 25 months (blinded central review) over placebo, and favorable hazard ratio of 0.30 and 0.25, respectively, confirming our view that the PARP’s are more similar than different. As such, we believe this provides a favorable readth

  • [By Ben Levisohn]

    Guggenheim’s Tony Butler and Kaitlin Sandor argue that Gilead Sciences (GILD) should buy Syndax Pharmaceuticals (SNDX), Corvus Pharmaceuticals (CRVS), and Tesaro (TSRO) to solve its problem of slowing sales:

Hot Performing Stocks To Own Right Now: JinkoSolar Holding Company Limited(JKS)

Advisors’ Opinion:

  • [By Lisa Levin]

    JinkoSolar Holding Co (NYSE: JKS) dropped 9.88% to $16.87 after the company announced the offering of 3,500,000 American Depositary Shares.

    Fuwei Films (Holdings) Co (NASDAQ: FFHL) dropped 9.66% to $1.30. Fuwei Films’ trailing-twelve-month ROE is -10.85%.

  • [By Elizabeth Balboa]

    First Solar, Inc (NASDAQ: FSLR) was trading down 3.7 percent Monday, while JA Solar Holdings Co., Ltd. (ADR) (NASDAQ: JASO) was down 0.8 percent, SunPower Corporation (NASDAQ: SPWR) 4.4 percent, Canadian Solar Inc. (NASDAQ: CSIQ) 5.2 percent and JinkoSolar Holding Co., Ltd. (NYSE: JKS) 4.4 percent.

  • [By Paul Ausick]

    But the real news is the near vertical trajectory in share prices for the two stocks. This could be another manifestation of the markets hunger for some momentum plays, as we noted earlier this morning the bump to share prices for both JinkoSolar Holding Co. Ltd. (NYSE: JKS) and Shutterstock Inc. (NASDAQ: SSTK), both of which held secondary share sales this morning.

  • [By Lisa Levin]

    In trading on Monday, energy shares fell by 0.59 percent. Meanwhile, top losers in the sector included JinkoSolar Holding Co., Ltd. (NYSE: JKS), down 8 percent, and Teekay Offshore Partners L.P. (NYSE: TOO) down 7 percent.

Hot Performing Stocks To Own Right Now: Xcel Energy Inc.(XEL)

Advisors’ Opinion:

  • [By Shauna O’Brien]

    Jefferies announced on Wednesday that it has raised its rating on Xcel Energy Inc (XEL).

    The firm has upgraded XEL from “Hold” to “Buy,” and has raised the company’s price target from $31 to $32.50. This new price target suggests a 15% upside from the stock’s current price of $27.72.

    Analyst Paul B. Fremont commented: “The stock is currently trading at an 8% P/E discount to our 2015E group average multiple.”

    “Despite a difficult political environment in Minnesota the company was able to achieve a reasonable outcome in its NSP-Minnesota rate case,” the analyst added.

    Looking forward, the firm has increased its FY2014 outlook from $1.95 to $2.00 per share.

    Xcel Energy shares were mostly flat during pre-market trading Wednesday. The stock has been mostly flat YTD.

Top 10 Performing Stocks To Buy For 2018

March 16, 2017: Markets opened higher again Thursday but the uptick did not last longer. Within an hour shares had dropped and a brief turn higher was foiled quickly. The worst performing sectors for the day are utilities and healthcare, with financials showing the only decent gain. WTI crude oil for April delivery settled at $48.75 a barrel, down 0.2% on the day. April gold added 2.2% on the day to settle at $1,227.10. Equities were headed for a lower close shortly before the bell as the DJIA traded down 0.11% for the day, the S&P 500 traded down 0.22%, and the Nasdaq Composite traded down 0.02%.

The DJIA stock posting the largest daily percentage loss ahead of the close Thursday was E.I. du Pont de Nemours Inc. (NYSE: DD) which traded down 1.14% at $80.56. The stock’s 52-week range is $61.12 to $81.51. Volume was roughly 40% below the daily average of around 2.6 million shares. The company had no specific news.

Chevron Corp. (NYSE: CVX) traded down 1.00% at $107.79. The stock’s 52-week range is $92.25 to $119.00. Volume was about 10% below the daily average of around 6.3 million shares. The integrated oil & gas company had no specific news.

Top 10 Performing Stocks To Buy For 2018: Tobira Therapeutics, Inc.(TBRA)

Advisors’ Opinion:

  • [By Benzinga News Desk]

    Allergan (NYSE: AGN) acquired Akarna Therapeutics global rights to AKN-083 for up-front payment of $50 million. This came just hours after Allergan bought Tobira Therapeutics (NASDAQ: TBRA) for upfront Payment of $28.35 share in cash, up to $49.84 per share in CVRs.

Top 10 Performing Stocks To Buy For 2018: TESARO, Inc.(TSRO)

Advisors’ Opinion:

  • [By George Budwell]

    Unfortunately for Clovis and its shareholders, though, Astra’s Lynparza is currently underpriority review with the FDA as a maintenance therapy in ovarian cancer, andTesaro’s (NASDAQ:TSRO)rival PARP inhibitor Zejula gained an early approval– along with afar broader label than Rubraca — just this week.

  • [By Ben Levisohn]

    Who has PARP? A poly ADP-ribose polymerase inhibitor (PARPi) kills cancer cells by interfering tumor DNA repair pathway with the potential to treat ovarian, breast and prostate cancer. Studies have shown that patients with BRCA mutations (BRCAmut) respond to PARPi. AstraZenecas (AZN) PARPi was approved in 2014 whileClovis Oncology (CLVS) and Tesaro (TSRO) both have positive Phase III data. Clovis licensed its PARPi from Pfizer (PFE) in 2011 and Tesaro licensed its PARPi from Merck (MRK) in 2012, after Sanofis (SNY) PARPi (later demonstrated that it cannot block PARP) failed in Phase III in early 2011.

  • [By Todd Campbell]

    The PARP battle is on. Following news that AstraZeneca’s (NYSE:AZN) PARP-inhibiting cancer drug Lynparza delivered a big win in phase 3 studies, all eyes now shift to how a potential Food and Drug Administration approval for Lynparza will reshape the commercial opportunity for competitor Tesaro Inc. (NASDAQ:TSRO).

  • [By Ben Levisohn]

    Shares of Tesaro (TSRO) are soaring today after the biotech company reported positive data for its treatment of ovarian cancer over the weekend. Credit Suisse analyst Alethia Young and team contend that “M&A remains in focus” for Tesaro following the data:

    Getty Images

    We are increasing our target price to $122 from $90 as we move to an M&A DCF valuation. We were at ESMO this weekend, and we believe the big takeaway on Tesaro data is that it works broadly in all 2L ovarian populations and safety looks solid. We also think the robustness of this data bodes well from PRIMA and QUADRA but are maintaining our POS here. We have looked at our model and also adjusted durations in first-line. We think Tesaro remains one of the most attractive and de-risked cancer assets in our landscape and the company has been cited in major press sources as a takeout target (Bloomberg, Investor Business Daily).

    We think M&A remains in focus for Tesaro. Our M&A DCF valuations range from $122 to $157 by our model. We have also built models for other cancers like NSCLC, SCLC, prostate, and others where PARP might be impactful. We assume 0% POS for now but we conservatively see at least another $1B in sales from PARP expansion. Tesaro has been cited in the press as a potential M&A target and is a company we frequently hear mentioned as a target from our conversations. We think the demand for late stage oncology assets is high, especially in the PARP space given the potential for activity across a range of tumors. For a large Pharma player who already has an oncology salesforce and large R&D infrastructure we could see SG&A synergies of 50-75% and R&D synergies of 15-30%. In our base case TSRO P&L we model a tax rate of 30% so there could be synergies here as well. Two additional key swing factors which might be included in a CVR are how much expansion from PARP in other cancers and immuno-oncology…

    Ex M&A,

  • [By Ben Levisohn]

    Look out below! Shares of Tesaro (TSRO) have dropped more than 10% this afternoon after AstraZeneca (AZN) released stronger-than-expected Phase 3 trial data on a its ovarian cancer treatment.

    Agence France-Presse/Getty Images

    The Street’sAdam Feuerstein has the details on AstraZeneca’s strong data and its impact on Tesaro:

    AstraZeneca’s (AZN) PARP inhibitor Lynparza delayed the recurrence of ovarian cancer by more than two years compared to a placebo, according to results from a phase III study presented Tuesday.

    The strong benefit observed with Lynparza as ovarian cancer maintenance therapy exceeded investor expectations and bolsters AstraZeneca against a competing PARP inhibitor from Tesaro (TSRO).

    Feuerstein also notes that AstraZeneca’s data could be good newsClovis Oncology (CLVS), which also had a PARP inhibitor approved recently, if it means that its drug could work as well as Astra’s.

    In February, Leerink cut Tesaro, arguing that the rally in its shares due to a potential takeover had run too far. Will it still be a takeover target?

    Shares of Tesaro have dropped 14% to $148.01 at 3:28 p.m. today, while AstraZeneca has gained 1.1% to $30.41, and Clovis Oncology has jumped 9.8% to$66.55.

    UPDATE:Piper Jaffray’sSteven Breazzano andJoshua Schimmer note that the AstraZeneca data shows that PARPs are “more similar than different.” They explain:

    This afternoon AstraZeneca (covered by PJC analyst Richard Purkiss) reported the detailed results from the SOLO-2 maintenance study of Lynparza in 2L+ ovarian cancer. The detailed data highlights a PFS benefit of 14 months (investigator assessed, and primary endpoint) and 25 months (blinded central review) over placebo, and favorable hazard ratio of 0.30 and 0.25, respectively, confirming our view that the PARP’s are more similar than different. As such, we believe this provides a favorable readth

Top 10 Performing Stocks To Buy For 2018: Cardiome Pharma Corporation(CRME)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of CARDIOME PHARMA CORP (NASDAQ: CRME) were down 30 percent to $2.72 after the company issued U.S. regulatory update for BRINAVESS. The FDA advised Cardiome that the data package proposed is not sufficient to support re-submission of the BRINAVESS NDA.

  • [By Lisa Levin]

    Shares of CARDIOME PHARMA CORP (NASDAQ: CRME) were down 43 percent to $3.01. Cardiome priced 10 million shares at $3 per share.

    Seadrill Partners LLC (NYSE: SDLP) was down, falling around 30 percent to $4.09 as the company announced plans to reduce the quarterly cash distribution to $0.10 per unit from $0.25 per unit.

Top 10 Performing Stocks To Buy For 2018: Blackrock Global(BOE)

Advisors’ Opinion:

  • [By Robert Rapier]

    Whiting Petroleum (WLL) is one of Continental’s biggest competitors in the Bakken. Whiting is the second-largest oil producer in North Dakota, averaging 82,500 barrels of oil equivalent (BOE) of production in 2012, across more than 700,000 acres of leased land.

Top 10 Performing Stocks To Buy For 2018: Atara Biotherapeutics, Inc.(ATRA)

Advisors’ Opinion:

  • [By Chris Lange]

    Atara Biotherapeutics Inc. (NASDAQ: ATRA) shares surged on Friday after the firm announced that it received clearance from the U.S. Food and Drug Administration (FDA) to initiate two Phase 3 clinical studies. Specifically these mid-stage studies deal with tabelecleucel in patients with rituximab-refractory Epstein-Barr virus (EBV) associated post-transplant lymphoproliferative disorder (EBV+PTLD).

Top 10 Performing Stocks To Buy For 2018: Clarke(t)

Advisors’ Opinion:

  • [By Jim Robertson]

    DirecTV is a direct broadcast satellite service provider and is a subsidiary of AT&T Inc (NYSE: T). Its satellite service, launched on June 17, 1994, transmits digital satellite television and audio to households in the United States, Latin America and the Caribbean withprimary competitorsbeing Dish Network and cable television providers. On July 24, 2015, after receiving approval from the FCC and United States Department of Justice, AT&T acquired DirecTV in a transaction valued at $48.5 billion. DirecTV would be paying$1.5 billion a year for the NFL Sunday Ticket.AT&T’s shares may have broken out of a downtrend:

  • [By Brian Feroldi, Dan Caplinger, Rich Duprey, Jason Hall, and Jordan Wathen]

    In order to point you in the right direction, we asked a team of Fools to highlight a dividend stock that they feel is a great stock for a beginner. Read on to see why they picked AT&T (NYSE:T),Apple (NASDAQ:AAPL),Anheuser-Busch InBev(NYSE:BUD), Mastercard(NYSE:MA), andJPMorgan Chase(NYSE:JPM).

  • [By Paul Ausick]

    AT&T Inc. (NYSE: T) dropped about 1.4% Tuesday to post a new 52-week low of $35.87 after closing Monday at $36.39. The 52-week high is $43.50. Volume was around 5.8 million shares traded, nearly 10 times the daily average of around 600,000. The company had no specific news.

  • [By Douglas A. McIntyre]

    At the other end of the iPhone 8 spectrum, wireless companies like AT&T Inc. (NYSE: T) probably will price the low-end version of the iPhone 8 below $40 a month, with 24-month contracts. This kind of price plan is a usual way for large wireless carriers to get and hold customers for long periods. Even if the carrier pays a lot for the smartphone, it presumably makes that back in monthly fees and on people who renew their subscriptions for a longer period.

  • [By Chris Lange]

    AT&T Inc.’s (NYSE: T) second-quarter results are scheduled for Tuesday. The consensus earnings estimate is $0.74 per share, on $39.82 billion in revenue. The shares were last seen at $36.51. The consensus price target is $40.27, and the 52-week trading range is $35.81 to $43.50.

Top 10 Performing Stocks To Buy For 2018: Snap-On Incorporated(SNA)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    Coming up on this episode of Mad Money: Cramer interviews Nick Pinchuk, CEO of Snap-on (SNA) . Plus, don’t miss the Lightning Round. Which stocks is Cramer bullish on?

  • [By John Divine]

    Snap-on Incorporated (SNA) is my choice for the Best Stocks for 2016 competition. At a market cap of $10 billion, I doubt it will double over the next year, as some of the smaller companies in this competition might be able to.

    That said, Snap-on, which manufactures and markets hand tools and diagnostic equipment, is a rock-solid company with an attractive valuation and impressive growth. It goes for 22 times earnings, pays a consistent and modest dividend, and has been around since 1920.

    As cars get more tech-heavy and complicated, newer tools and better diagnostics will be needed — and that’s SNA’s bread ‘n’ butter. 

  • [By WWW.MONEYSHOW.COM]

    Snap-on (SNA)

    Snap-on, which is more than 100 years old, provides hand and power tools for individuals and professionals, including auto-shop tools and auto diagnostic equipment.

Top 10 Performing Stocks To Buy For 2018: PRA Group, Inc.(PRAA)

Advisors’ Opinion:

  • [By Lee Jackson]

    PRA Group Inc. (NASDAQ: PRAA) has been hit hard recently, and shareholders may be glad to know that a director took advantage of the sell-off and stepped in to buy shares. That board member bought 143,000 shares of the financial and business services company at prices that ranged from $34.40 to $34.89. The total for the buy was set at $5 million. The stock closed Friday at $32.90, in a52-week range of $21.93 to $42.70. The consensus price target is $40.60.

Top 10 Performing Stocks To Buy For 2018: Tyson Foods Inc.(TSN)

Advisors’ Opinion:

  • [By Lisa Levin] Companies Reporting Before The Bell
    Tyson Foods, Inc. (NYSE: TSN) is expected to report quarterly earnings at $1.38 per share on revenue of $9.86 billion.
    Aecom (NYSE: ACM) is projected to report quarterly earnings at $0.71 per share on revenue of $4.67 billion.
    JD.Com Inc(ADR) (NASDAQ: JD) is estimated to report quarterly earnings at $0.11 per share on revenue of $12.60 billion.
    58.com Inc (ADR) (NYSE: WUBA) is projected to report quarterly earnings at $0.28 per share on revenue of $383.60 million.
    Kamada Ltd (NASDAQ: KMDA) is expected to report quarterly earnings at $0.02 per share on revenue of $25.00 million.
    Palatin Technologies, Inc. (NYSE: PTN) is projected to report quarterly earnings at $0.06 per share on revenue of $28.00 million.
    TheStreet, Inc. (NASDAQ: TST) is estimated to report a quarterly loss at $0.02 per share on revenue of $15.81 million.
    Atlantica Yield PLC (NASDAQ: ABY) is projected to report quarterly earnings at $0.45 per share on revenue of $290.80 million.
    Asure Software Inc (NASDAQ: ASUR) is estimated to report quarterly earnings at $0.15 per share on revenue of $15.26 million.
    Cyren Ltd (NASDAQ: CYRN) is expected to report quarterly loss at $0.06 per share on revenue of $7.90 million.
    Viewray Inc (NASDAQ: VRAY) is estimated to report quarterly loss at $0.12 per share on revenue of $18.58 million.

     

  • [By Peter Graham]

    A long term performance chart shows shares ofmid cap Sanderson Farms more than doubling in value while large cap Tyson Foods, Inc (NYSE: TSN)has more than tripled in value and mid cap Pilgrim’s Pride Corporation (NASDAQ: PPC) has quadrupled in value:

  • [By Peter Graham]

    A long term performance chart shows shares of small cap Sanderson Farms doubling in value while mid cap Pilgrim’s Pride Corporation (NASDAQ: PPC) and large cap Tyson Foods, Inc (NYSE: TSN) have been even better performers albeit shares are below their peaks and have been somewhat volatile:

Top 10 Performing Stocks To Buy For 2018: Oasis Petroleum Inc.(OAS)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Oasis Petroleum Inc. (NYSE: OAS) were down 14 percent to $8.60 after the company reported a 32 million share common stock offering. The company announced Delaware Basin acquisition for $946 million and also raised its Q4 production guidance.

  • [By Jon C. Ogg]

    Oasis Petroleum Inc. (NYSE: OAS) rose a whopping 27.8% to $14.98, and the 33.2 million shares was about 2.5 times normal volume. Oasis Petroleum has a 52-week trading range of $3.40 to $15.02 and a consensus analyst price target of $14.54. The company has a total market cap of $3.5 billion.

  • [By Chris Lange]

    Oasis Petroleum Inc. (NYSE: OAS) shares slid on Tuesday after the company announced that it would be buying into the Delaware Basin. Analysts seemed to applaud this move, despite investors sending shares into the fire. Jefferies raised its price target to $14 from $13, and Morgan Stanley raised its target to $11 from $9. RBC has an Outperform rating and raised its target to $14 from $13, while SunTrust Robinson Humphrey downgraded it to Hold from Buy. Shares were down about 14% at $8.67, in a 52-week range of $6.69 to $16.73.

  • [By Paul Ausick]

    Oasis Petroleum Inc. (NYSE: OAS) is rated a Buy and the price target was lifted to $24. For 2017, the net loss estimate improved from a prior $0.27 per share to $0.23 per share. The 2018 EPS estimate rose from $0.62 to $0.64. Shares closed at $14.13 on Friday. The 52-week range is $5.93 to $14.35, and the consensus 12-month target is $17.87.

  • [By Craig Jones]

    Jon Najarian spoke on CNBC’s “Fast Money Halftime Report” about unusually high options activity in Oasis Petroleum Inc. (NYSE: OAS).

    Traders bought around 10,000 contracts of the June 10 calls in the first half of the trading session on Thursday. The trade is unusual because the average options volume in the name is a few hundred contracts. Najarian bought the calls and is planning to hold them for two weeks.

Top 10 Undervalued Stocks To Invest In Right Now

Over the past year, the performance of T. Rowe Price Blue Chip Growth (TRBCX has underscored why it pays to sit tight when a fund with a superior long-term record hits a speed bump. In 2016, as investors turned away from shares of the fast-growing, large-capitalization stocks that Blue Chip targets in favor of more-undervalued fare, the fund lagged the stock market dramatically. Stocks that had previously buoyed the fund, such as Amazon.com and Facebook, were suddenly a drag, says manager Larry Puglia. And energy and utility stockssectors that Blue Chip tends to ignoreperformed exceptionally well.

See Also: Kip 25 Best No-Load Mutual Funds 2017

But these kinds of style shifts dont last forever. Large-cap growth stocks, led by the technology sector, are rebounding this year, and Blue Chip is benefiting. In the first three months of 2017, the fund returned 10.4%, beating Standard & Poors 500-stock index by 4.3 percentage points. Over the past 12 months, Blue Chip, a member of the Kiplinger 25, outpaced the index by nearly a full percentage point. (Prices and returns are through March 31)

Top 10 Undervalued Stocks To Invest In Right Now: L-3 Communications Holdings, Inc.(LLL)

Advisors’ Opinion:

  • [By Paul Ausick]

    Five teams are expected to compete for the contract: Boeing Co. (NYSE: BA) has joined with Saab to offer a clean-sheet design; Northrop Grumman Corp. (NYSE: NOC) has teamed up with BAE Systems and L-3 Communications Holdings Inc. (NYSE: LLL) on another clean-sheet design; Lockheed Martin Corp. (NYSE: LMT) and Korea Aerospace Industries (KAI) are going with a modified KAI T-50; Raytheon Corp. (NYSE: RTN) has joined with Italy’s Leonardo and Canada’s CAE Inc. (NYSE: CAE) on a version of Leonardo’s M-346 trainer that it calls the T-100; and privately held Sierra Nevada has partnered with Turkish Aerospace Industries (TAI) on another clean-sheet design.

  • [By Peter Graham]

    A long term performance chart shows ViaSat, Inc plus mid to large cap communications stockslikeHarris Corporation (NYSE: HRS) and L-3 Communications Holdings, Inc (NYSE: LLL)had been moving in tandem until last yearwhile small cap Gogo Inc has underperformed:

  • [By Peter Graham]

    Headquartered in New York City, large cap L3 Technologies Inc (NYSE: LLL) employs approximately 38,000 people worldwide and is a leading provider of a broad range of communication, electronic and sensor systems used on military, homeland security and commercial platforms. L3 is also a prime contractor in aerospace systems, security and detection systems, and pilot training. The Company reported 2016 sales of $10.5 billion.

Top 10 Undervalued Stocks To Invest In Right Now: Salesforce.com Inc(CRM)

Advisors’ Opinion:

  • [By WWW.MONEYSHOW.COM]

    Cloud-software leader Salesforce (CRM) – my Top Pick for 2017 among large cap technology stocks — remains well positioned to reap the benefits of the transition away from on-premises solutions.

  • [By WWW.THESTREET.COM]

    “There are two things that mess up your relationships, it’s anger and fear,” explains Robbins. Robbins points to Salesforce (CRM) CEO Marc Benioff as being a total giver, which has set him up for success in business.

  • [By Peter Graham]

    On the earnings call, Ellison noted that the company had surpassed Salesforce.com, inc (NYSE: CRM) in annualized recurring cloud revenue: We are now well on our way to passing them and becoming number one in the enterprise SaaS market.”

Top 10 Undervalued Stocks To Invest In Right Now: TG Therapeutics, Inc.(TGTX)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    In the Lightning Round, Cramer was bullish on Treehouse Foods (THS) , TG Therapeutics (TGTX) , Kinder Morgan (KMI) , Magellan Midstream Partners (MMP) , Chesapeake Energy (CHK) and Arconic (ARNC) .

  • [By Lisa Levin]

    Benzinga's newsdesk monitors options activity to notice unusual patterns. These large volume (and often out of the money) trades were initially published intraday in Benzinga Professional . These trades were placed during Thursday's regular session.

  • [By Brian Orelli]

    TG Therapeutics (NASDAQ:TGTX)rose 15% today, after an analyst at Jefferies initiated coverage with a buy and a $23 price target.

    So what

    Analyst action often has an effect on company’s stock price, especially in the short term, but today’s move may be exacerbated by an upcoming data release at the American Academy of Neurology meeting scheduled for Friday. Investors may have been jumping in today ahead of the binary event, hoping that Friday’s data will be positive enough to send the share price even higher.

Top 10 Undervalued Stocks To Invest In Right Now: TESARO, Inc.(TSRO)

Advisors’ Opinion:

  • [By Todd Campbell]

    Tesaro’s (NASDAQ:TSRO)ovarian cancer drug, niraparib, will begin competing for prescriptions earlier than expected. Niraparib, which will be sold under the brand name Zejula, notched FDA approval on Monday, more than three months ahead of its June 30 decision date. The early approval setsTesaro up for a fierce battle for market share withAstraZeneca (NYSE:AZN)and Clovis Oncology (NASDAQ:CLVS), both of which market drugs that work similarly to Zejula.

  • [By Ben Levisohn]

    Shares of Tesaro (TSRO) are soaring today after the biotech company reported positive data for its treatment of ovarian cancer over the weekend. Credit Suisse analyst Alethia Young and team contend that “M&A remains in focus” for Tesaro following the data:

    Getty Images

    We are increasing our target price to $122 from $90 as we move to an M&A DCF valuation. We were at ESMO this weekend, and we believe the big takeaway on Tesaro data is that it works broadly in all 2L ovarian populations and safety looks solid. We also think the robustness of this data bodes well from PRIMA and QUADRA but are maintaining our POS here. We have looked at our model and also adjusted durations in first-line. We think Tesaro remains one of the most attractive and de-risked cancer assets in our landscape and the company has been cited in major press sources as a takeout target (Bloomberg, Investor Business Daily).

    We think M&A remains in focus for Tesaro. Our M&A DCF valuations range from $122 to $157 by our model. We have also built models for other cancers like NSCLC, SCLC, prostate, and others where PARP might be impactful. We assume 0% POS for now but we conservatively see at least another $1B in sales from PARP expansion. Tesaro has been cited in the press as a potential M&A target and is a company we frequently hear mentioned as a target from our conversations. We think the demand for late stage oncology assets is high, especially in the PARP space given the potential for activity across a range of tumors. For a large Pharma player who already has an oncology salesforce and large R&D infrastructure we could see SG&A synergies of 50-75% and R&D synergies of 15-30%. In our base case TSRO P&L we model a tax rate of 30% so there could be synergies here as well. Two additional key swing factors which might be included in a CVR are how much expansion from PARP in other cancers and immuno-oncology…

    Ex M&A,

  • [By Ben Levisohn]

    Look out below! Shares of Tesaro (TSRO) have dropped more than 10% this afternoon after AstraZeneca (AZN) released stronger-than-expected Phase 3 trial data on a its ovarian cancer treatment.

    Agence France-Presse/Getty Images

    The Street’sAdam Feuerstein has the details on AstraZeneca’s strong data and its impact on Tesaro:

    AstraZeneca’s (AZN) PARP inhibitor Lynparza delayed the recurrence of ovarian cancer by more than two years compared to a placebo, according to results from a phase III study presented Tuesday.

    The strong benefit observed with Lynparza as ovarian cancer maintenance therapy exceeded investor expectations and bolsters AstraZeneca against a competing PARP inhibitor from Tesaro (TSRO).

    Feuerstein also notes that AstraZeneca’s data could be good newsClovis Oncology (CLVS), which also had a PARP inhibitor approved recently, if it means that its drug could work as well as Astra’s.

    In February, Leerink cut Tesaro, arguing that the rally in its shares due to a potential takeover had run too far. Will it still be a takeover target?

    Shares of Tesaro have dropped 14% to $148.01 at 3:28 p.m. today, while AstraZeneca has gained 1.1% to $30.41, and Clovis Oncology has jumped 9.8% to$66.55.

    UPDATE:Piper Jaffray’sSteven Breazzano andJoshua Schimmer note that the AstraZeneca data shows that PARPs are “more similar than different.” They explain:

    This afternoon AstraZeneca (covered by PJC analyst Richard Purkiss) reported the detailed results from the SOLO-2 maintenance study of Lynparza in 2L+ ovarian cancer. The detailed data highlights a PFS benefit of 14 months (investigator assessed, and primary endpoint) and 25 months (blinded central review) over placebo, and favorable hazard ratio of 0.30 and 0.25, respectively, confirming our view that the PARP’s are more similar than different. As such, we believe this provides a favorable readth

  • [By Ben Levisohn]

    Guggenheim’s Tony Butler and Kaitlin Sandor argue that Gilead Sciences (GILD) should buy Syndax Pharmaceuticals (SNDX), Corvus Pharmaceuticals (CRVS), and Tesaro (TSRO) to solve its problem of slowing sales:

  • [By George Budwell]

    Unfortunately for Clovis and its shareholders, though, Astra’s Lynparza is currently underpriority review with the FDA as a maintenance therapy in ovarian cancer, andTesaro’s (NASDAQ:TSRO)rival PARP inhibitor Zejula gained an early approval– along with afar broader label than Rubraca — just this week.

  • [By Todd Campbell]

    The PARP battle is on. Following news that AstraZeneca’s (NYSE:AZN) PARP-inhibiting cancer drug Lynparza delivered a big win in phase 3 studies, all eyes now shift to how a potential Food and Drug Administration approval for Lynparza will reshape the commercial opportunity for competitor Tesaro Inc. (NASDAQ:TSRO).

Top 10 Undervalued Stocks To Invest In Right Now: Intercontinental Exchange Inc.(ICE)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    In the Lightning Round, Cramer was bullish on Altria (MO) , Intercontinental Exchange (ICE) and Micron Technology (MU) .

    Cramer was bearish on NVIDIA (NVDA) and Reynolds American (RAI) .

Top 10 Undervalued Stocks To Invest In Right Now: Exactech Inc.(EXAC)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Aimmune Therapeutics Inc (NASDAQ: AIMT) shares jumped 35 percent to $34.64 in response to failed DBVT peanut allergy trial.
    Exactech, Inc. (NASDAQ: EXAC) shares surged 30.9 percent to $41.88 after the company agreed to be acquired by TPG Capital for $42 per share in cash.
    Dextera Surgical Inc (NASDAQ: DXTR) shares climbed 27.6 percent to $0.238 after surging 40.48 percent on Friday.
    Petmed Express Inc (NASDAQ: PETS) jumped 21.8 percent to $44.73 as the company reported better-than-expected Q2 results.
    SenesTech Inc (NASDAQ: SNES) shares surged 21.7 percent to $1.95 after the company disclosed that Univar will be marketing and selling ContraPest.
    Yulong Eco-Materials Ltd (NASDAQ: YECO) shares gained 18.3 percent to $0.560.
    One Horizon Group Inc (NASDAQ: OHGI) shares rose 18 percent to $1.18.
    Atossa Genetics Inc (NASDAQ: ATOS) shares climbed 18 percent to $0.566. Atossa Genetics is schedule to host a conference call to announce preliminary results from Phase 1 study of oral Endoxifen on October 25, 2017.
    ReneSola Ltd. (ADR) (NYSE: SOL) shares rose 15.3 percent to $2.72
    Renren Inc (NYSE: RENN) shares gained 11.9 percent to $10.71 after gaining 2.68 percent on Friday.
    Kalvista Pharmaceuticals Inc (NASDAQ: KALV) shares rose 11.8 percent to $12.59. KalVista Pharma 13D filing from Longwood Fund showed registration for an 8.7 percent stake.
    Xunlei Ltd (NASDAQ: XNET) shares gained 9.4 percent to $7.20 after surging 25.33 percent on Friday.
    VF Corp (NYSE: VFC) shares surged 7.1 percent to $71.09 after the company reported upbeat earnings for its third quarter and raised its FY2017 guidance.
    CAI International Inc (NYSE: CAI) rose 6.6 percent to $39.70. Cowen & Co. upgraded CAI from Market Perform to Outperform.
    Agenus Inc (NASDAQ: AGEN) shares gained 5.7 percent to $4.58 as the company disclosed that GSK's shingle vaccine received FDA approval.
    Deltic Timber Corp (NYSE: DEL) shares climbed 5.6 percent to $94.11
  • [By Lisa Levin]

    Exactech, Inc. (NASDAQ: EXAC) shares were also up, gaining 31 percent to $41.88 after the company agreed to be acquired by TPG Capital for $42 per share in cash.

Top 10 Undervalued Stocks To Invest In Right Now: Cemex S.A.B. de C.V.(CX)

Advisors’ Opinion:

  • [By WWW.MONEYSHOW.COM]

    Cemex SAB de CV (CX) is very interesting at these levels as it seems the market is pricing in a stronger dollar (thereby reducing revenue) and thus lower growth.

  • [By Paul Ausick]

    Cemex SAB de CV (NYSE: CX) dropped about 2.4% Friday to post a new 52-week low of $7.41 after closing at $7.59 on Thursday. The 52-week high is $10.37. Volume was around 8.8 million, about 15% below the daily average of around 9.3 million. The Mexico-based cement company had no specific news.

  • [By Paul Ausick]

    Cemex SAB de CV (NYSE: CX) dropped about 2.7% Thursday to post a new 52-week low of $7.57 after closing at $7.78 on Wednesday. The 52-week high is $10.37. Volume was around 6.8 million, about 15% below the daily average of around 8.3 million. The Mexico-based cement company had no specific news.

  • [By Paul Ausick]

    Cemex SAB de CV (NYSE: CX) dropped about 1.8% Wednesday to post a new 52-week low of $7.16 after closing at $7.29 on Tuesday. The 52-week high is $10.37. Volume was around 7 million, about 20% below the daily average of around 9.5. The Mexico-based cement company had no specific news.

Top 10 Undervalued Stocks To Invest In Right Now: Ultragenyx Pharmaceutical Inc.(RARE)

Advisors’ Opinion:

  • [By Jon C. Ogg]

    Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) was indicated down 7% at $72.85 on Thursday due to results from a seizure medication study. It was downgraded to Neutral from Overweight at Piper Jaffray, and Wedbushlowered its target for the stock.

  • [By Lisa Levin] Related Mid-Afternoon Market Update: CytomX Therapeutics Climbs Following Bristol-Myers Squibb Partnership; Medgenics Shares Slide 15 Biggest Mid-Day Losers For Monday Cerulean Pharma's (CERU) CEO Chris Guiffre on Cerulean and Dar茅 Proposed Transaction (Transcript) (Seeking Alpha)
    Related Mid-Afternoon Market Update: Cancer Genetics Gains After Q4 Results; Heat Biologics Shares Slide Mid-Day Market Update: Dow Rises Over 50 Points; Tandem Diabetes Care Shares Plunge Tandem Diabetes prices stock offering at $1.25; shares off 19% premarket (Seeking Alpha)
    Cerulean Pharma Inc (NASDAQ: CERU) shares dipped 27 percent to $0.817. Cerulean Pharma shares have dropped 60.28 percent over the past 52 weeks, while the S&P 500 index has gained 15.31 percent in the same period.
    Tandem Diabetes Care Inc (NASDAQ: TNDM) shares tumbled 24.2 percent to $1.17. Tandem Diabetes Care priced 18 million share offering at $1.25 per share.
    Alphatec Holdings Inc (NASDAQ: ATEC) shares fell 21.1 percent to $2.10 as the company reported a $18.9 million private placement.
    Heat Biologics Inc (NASDAQ: HTBX) shares dropped 15.5 percent to $0.870. Heat Biologics priced its 5 million share offering at $0.80 per share.
    Rave Restaurant Group Inc (NASDAQ: RAVE) shares fell 15 percent to $1.76.
    QuickLogic Corporation (NASDAQ: QUIK) shares declined 12.2 percent to $1.58. QuickLogic priced its 10 million share offering at $1.50 per share.
    Orion Engineered Carbons SA (NYSE: OEC) shares dropped 9.5 percent to $19.10. Orion Engineered Carbons reported a 5 million common stock secondary offering.
    Interpace Diagnostics Group Inc (NASDAQ: IDXG) shares fell 8.7 percent to $2.61 after the company reported debt restructuring and agreed to eliminate its royalty and mileston
  • [By Johanna Bennett]

    Nothing guts a drug stock like bad clinical trial data. Shares of Ultragenyx Pharmaceutical (RARE) fell as much as 10% after a seizure medication failed in a phase II study.

    Trading at a recent $72.22, the shares were down 7.7% after earlier falling as much as 10% to $70.51

    The seizure drug UX007 was tested as a treatment for glucose transporter type-1 deficiency syndromeor Glut1 DSamong a small group of patients. Data released Wednesday showed that it only cut the rate of seizures in the drug arm by 13.4% compared to the placebo arm, falling short of statistical significance.

    Investigators, though, teased out a clinically — though not statistically — significant benefit for patients experiencing what are called absence seizures. Ultragenyx now intends to focus on that in a Phase III pivotal trial.

    Leerik analyst Joseph Schwartz called the selloff a buying opportunity.

    We had been cautious on this asset (and its two programs – G1DS and long-chain fatty acid oxidation disorder/LC-FAOD; LINK) – but believe the selling pressure after mkt. presents a buying opportunity ahead of a more de-risked X-linked hypophosphatemia (XLH) Ph.3 data in 1H17.

    Cowen analyst Eric Schmidt remained convinced of RAREs long-term prospects thanks to a diversified orphan disease pipeline. And analysts at Credit Suisse see more catalysts ahead in 2017.

    We are buyers on a pullback and we like RAREs setup for the remainder of 2017…Remaining 2017 catalysts keep us buyers on a pullback: We see Q2:17 KRN23 ph3 adult XLH data, H1:17 rhGUS FDA/EMA submission, potential KRN23 CHMP decision in mid-17 (based on late-2016 EMA submission/validation), H2:17 Ace-ER ph3 GNEM data, and potential KRN23 FDA submission in late-17/early-18 as upcoming catalysts worth owning for.

Top 10 Undervalued Stocks To Invest In Right Now: Century Aluminum Company(CENX)

Advisors’ Opinion:

  • [By Craig Jones]

    JPMorgan’s analyst Michael Gambardella downgraded Century Aluminum Co (NASDAQ: CENX) from Overweight to Neutral and reduced its price target from $22 to $14.50, citing alumina cost headwinds as the main reason for the downgrade.

Top 10 Undervalued Stocks To Invest In Right Now: Lithium X Energy Corp. (LIXXF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    The other producing lithium miners, and soon to be producers. I have discussed these previously in detail here, here and here. Needless to say, the top 3 producers are non-pure plays (SQM (NYSE:SQM), Albemarle (NYSE:ALB), and FMC Corp. (NYSE:FMC)). The top pure play currently producing miners are Orocobre (ASX:ORE) (OTCPK:OROCF), Tianqi Lithium (SHE:002466), Jiangxi Ganfeng Lithium, Galaxy Resources, Mineral Resources [ASX:MIN] (OTC:MALRF), and Neometals [ASX:NMT] (OTC:RRSSF). The near-term producers include Altura Mining [ASX:AJM] (OTCPK:ALTAF), Pilbara Minerals (ASX:PLS) (OTC:PILBF), Kidman Resources (ASX:KDR), Critical Elements, Nemaska Lithium (OTCQX:NMKEF) [TSX:NMX], Lithium Americas (OTCQX:LACDF) [TSX:LAC], Lithium X (OTCQX:LIXXF) (TSXV:LIX), Neo Lithium, and Bacanora Minerals (OTC:BCRMF) [TSXV:BCN], Advantage Lithium (OTCQB:AVLIF) [AAL], European Metals (OTCPK:MNTCF, ASX:EMH, AIM:EMH) and Pure Energy (OTCQB:PEMIF) [PE].

  • [By Tom Bishop]

    Lithium X Energy NPV (LIXXF) owns 50% of the Sal de los Angeles lithium brine project in the prolific “Lithium Triangle” in mining friendly Salta province, Argentina.